Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528917 · ClinicalTrials.gov registry record
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 49
- Enrollment target
NCT01528917: Completed study, sponsored by Alexion Pharmaceuticals.
NCT01528917 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01528917 has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
This is a Natural History study to characterize key aspects of the clinical course of late onset Lysosomal Acid Lipase (LAL) Deficiency/ Cholesteryl Ester Storage Disease (CESD).
Primary Outcome
Characterize patient demographic data and clinical course of disease using descriptive statistics.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-05 |
What the finished NCT01528917 record still lists
NCT01528917 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01528917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01528917 about?
NCT01528917 is a clinical study titled "An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype". This is a Natural History study to characterize key aspects of the clinical course of late onset Lysosomal Acid Lipase (LAL) Deficiency/ Cholesteryl Ester Storage Disease (CESD).
What is the current status of trial NCT01528917?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2011-06. Estimated completion is 2013-05.
Who is sponsoring clinical trial NCT01528917?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia